Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment

Drug Safety

Volumn 39, Issue 7, 2016, Pages 589-611

  Smolders, Elise J ^a   de Kanter, Clara T M M ^b   van Hoek, Bart ^c   Arends, Joop E ^b   Drenth, Joost P H ^a   Burger, David M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ASUNAPREVIR; DACLATASVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; ELBASVIR PLUS GRAZOPREVIR; LEDIPASVIR PLUS SOFOSBUVIR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; SOFOSBUVIR PLUS VELPATASVIR;

ANEMIA; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ASTHENIA; CARDIOTOXICITY; DIARRHEA; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; ELIMINATION HALF-LIFE; FATIGUE; HEADACHE; HEPATITIS C; HUMAN; INSOMNIA; KIDNEY DISEASE; LIVER DISEASE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; STEADY STATE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VOLUME OF DISTRIBUTION; CHRONIC HEPATITIS C; CHRONIC KIDNEY FAILURE; LIVER CIRRHOSIS; METABOLISM; VIROLOGY;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; KIDNEY FAILURE, CHRONIC; LIVER CIRRHOSIS;

EID: 84964339336     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-016-0420-2     Document Type: Review

References (96)

1. Singal AK, Guturu P, Hmoud B, Kuo YF, Salameh H, Wiesner RH. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation. 2013;95(5):755–60. doi:10.1097/TP.0b013e31827afb3a.
2. Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med. 2013;19(7):850–8. doi:10.1038/nm.3184.
3. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1 Suppl.):S45–57. doi:10.1016/j.jhep.2014.07.027.
4. WHO. Hepatitis C fact sheet. 2014. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed 15 May 2014.
5. Highleyman L. Hepatitis C: the changing picture. 2009. http://www.thebody.com/content/art53550.html. Accessed 14 Jan 2016.
6. Verbeeck R. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147–61. doi:10.1007/s00228-008-0553-z.
7. Fukazawa K, Lee HT. Updates on hepato-renal syndrome. J Anesth Clin Res. 2013;4(9):352. doi:10.4172/2155-6148.1000352.
8. Sun H, Frassetto L, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Ther. 2006;109(1–2):1–11. doi:10.1016/j.pharmthera.2005.05.010.
9. EASL. EASL recommendations on treatment of hepatitis C 2015. 2015. http://www.easl.eu/research/our-contributions/clinical-practice-guidelines/detail/recommendations-on-treatment-of-hepatitis-c-2015/report/1. Accessed 8 June 2015.
10. AASLD. HCV guidance: recommendations for testing, managing, and treating hepatitis C. 2015. http://www.hcvguidelines.org/. Accessed 27 Jan 2016.
11. EMA. Olysio product information. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002777/WC500167867.pdf. Accessed 29 Sept 2015.
12. Ouwerkerk-Mahadevan S, Simion A, Spittaels K, Beumont-Mauviel M. Pharmacokinetics of simeprevir (TMC435) in volunteers with moderate or severe hepatic impairment [abstract no. 887]. J Hepatol. 2013;58(Suppl. 1):S229. doi:10.1016/S0168-8278(13)60889-2.
13. Sekar V, Simion A, Peeters M, Spittaels K, Lawitz E, Marbury TC, et al. Pharmacokinetics of TMC435 in subjects with moderate hepatic impairment [abstract no. 472]. J Hepatol. 2011;54(Suppl. 1):S193. doi:10.1016/S0168-8278(11)60474-1.
14. Eley T, He B, Chang I, Colston E, Child M, Bedford W, et al. The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor. Antivir Ther. 2015;20(1):29–37. doi:10.3851/imp2773.
15. Eley T, Garimella T, Li W, Bertz RJ. Asunaprevir: a review of preclinical and clinical pharmacokinetics and drug-drug interactions. Clin Pharmacokinet. 2015;54(12):1205–22. doi:10.1007/s40262-015-0299-6.
16. Garimella T, He B, Luo WL, Colston E, Zhu LM, Kandoussi H, et al. Asunaprevir pharmacokinetics and safety in subjects with impaired renal function [abstract no. 463]. 64th annual meeting of the american association for the study of liver diseases, 1–3 Nov 2013, Washington, DC.
17. Adamczyk R, Sims K, Hesney M, Wind-Rotolo M, Stonier M, Penn R, et al. The effect of renal impairment on multiple-dose pharmacokinetics of the fixed-dose combination of daclatasvir/asunaprevir/beclabuvir. J Hepatol. 2015;62(Suppl. 2):S628. doi:10.1016/S0168-8278(15)30993-4.
18. EMA. Daklinza product information. 2015. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003768/WC500172848.pdf. Accessed 29 Sept 2015.
19. Bifano M, Sevinsky H, Persson A, Chung E, Wind-Rotolo M, Hwang C, et al. Single-dose pharmacokinetics of daclatasvir (DCV; BMS-790052) in subjects with hepatic impairment compared with healthy subjects [abstract no. 1004A]. 62nd annual meeting of the American association for the study of liver diseases, 6–9 Nov 2011, San Fransisco.
20. Garimella T, Wang R, Luo WL, Hwang C, Sherman D, Kandoussi H, et al. Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment. Antivir Ther. 2015;5:535–43. doi:10.3851/imp2941.
21. EMA. Harvoni product information. 2015. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003850/WC500177995.pdf. Accessed 29 Sept 2015.
22. FDA. Sovaldi prescribing information. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204671s000lbl.pdf. Accessed 25 Jan 2016.
23. EMA. Sovaldi product information. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002798/WC500160597.pdf. Accessed 29 Sep 2015.
24. Lawitz E, Rodriguez-Torres M, Cornpropst M, Denning JM, Clemons D, McNair L, et al. The effect of hepatic impairment on the safety, pharmacokinetics, and antiviral activity of PSI-7977 in hepatitis C infected subjects treated for seven days [abstract no. 1130]. J Hepatol. 2012;56(Suppl. 2):S445–6. doi:10.1016/S0168-8278(12)61142-8.
25. Cornpropst MT, Dennning JM, Clemons D, Marbury TC, Alcorn H, Smith WB, et al. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of GS-7977 [abstract no. 1101]. J Hepatol. 2012;56(Suppl. 2):S433. doi:10.1016/S0168-8278(12)61113-1.
26. Desnoyer A. Sofosbuvir in hemodialysis: 400mg daily of only the day of hemodialysis? [abstract no. 19]. 16th international workshop of clincial pharmacology of HIV and hepatitis therapy, 26 May 2015, Washington, DC.
27. Gane EJ, Robson RA, Bonacine M, Maliakkal B, Kirby B, Liu LJ, et al. Safety, antiviral efficacy, and pharmacokinetics of sofosbuvir in patients with severe renal impairment [abstract no. 966]. 65th annual meeting of the American association for the study of liver diseases, 7 Nov 2014, Boston, MA.
28. Liu L, Sajwani K, Kirby B, Denning J, Stamm LM, Brainard D, et al. Safety and efficacy of treatment with daily sofosbuvir 400mg + ribavirin 200mg for 24 weeks in genotype 1 and 3 HCV-infected patients with severe renal impairment. 66th annual meeting of the American association for the study of liver diseases, 13–17 Nov 2015, San Fransisco.
29. Gilead Sciences. Sofosbuvir plus ribavirin, or ledipasvir/sofosbuvir in adults With HCV infection and renal insufficiency [ClinicalTrials.gov Identifier: NCT01958281]. US National institues of Health, ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01958281. Accessed 14 Mar 2016.
30. FDA. Clinical Pharmacology and Biopharmaceutics review(s): sovaldi (sofosbuvir). 2013. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204671Orig1s000ClinPharmR.pdf. Accessed 04 Mar 2016.
31. Saxena V, Koraishy FM, Sise M, Lim JK, Chung RT, Liapakis A, et al. Safety and efficacy of sofosbuvir-containing regimines in hepatitis C infected patients with reduces renal function: real-world experience from HCV-TARGET [abstract no. LP08]. J Hepatol. 2015;62(Suppl. 2):S267. doi:10.1016/S0168-8278(15)30162-8.
32. Yeh WW, Caro L, Guo Z, Feng HP, Davis H, Kozisek M, et al. Pharmacokinetics of co-administered HCV protease inhibitor grazoprevir (MK-5172) and NS5A inhibitor elbasvir (MK-8742) in volunteers with end-stage renal disease on hemodialysis or sever renal impairment not on hemodialysis [poster no. 1940]. 65th annual meeting of the American association for the study of liver diseases, 7 Nov 2014, Boston, MA.
33. Nazario HE, Ndungu M, Modi AA. Sofosbuvir and simeprevir in hepatitis C genotype 1- patients with end-stage renal disease on hemodialysis or GFR <30mL/min. Liver Int. 2015. doi:10.1111/liv.13025.
34. German P, Mathias A, Yang JC, McNair L, Shen G, Vimal M, et al. Pharmacokinetics of ledipasvir, an HCV-specific NS5A inhibitor, in HCV-uninfect subjects with moderate or severe hepatic impairment [abstract no. 1952]. 64th annual meeting of the American association for the study of liver diseases, 1–3 Nov 2013, Washington, DC.
35. Mogalian E, Mathias A, Yang J, Moorehead L, Hernandez J, Lasseter K, et al. The pharmacokinetics of ledipasvir, an HCV-specific NS5A inhibitor, in HCV-uninfected subjects with severe renal impairment [abstract no. 1952]. 65th annual meeting of the American association for the study of liver diseases, 7–11 Nov 2014, Boston, MA.
36. Foster GR, Afdhal N, Roberts SK, Brau N, Gane EJ, Pianko S, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373(27):2608–17. doi:10.1056/NEJMoa1512612.
37. Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599–607. doi:10.1056/NEJMoa1512610.
38. Mogalian E, German P, Yang CY, Moorehead L, Brainard D, McNally J, et al. Evaluation of transporter and cytochrome P450-mediated drug-drug interactions between pan-genotypic HCV NS5A inhibitor GS-5816 and phenotypic probe drugs [abstract O_07]. 15th international workshop on clinical pharmacology of HIV & hepatitis therapy, 19–21 May 2014, Washington, DC.
39. Mogalian E, German P, Kearney BP, Yang CY, Brainard D, McNally J, et al. Use of multiple probes to assess transporter- and cytochrome P450-mediated drug-drug interaction potential of the pangenotypic hcv NS5A inhibitor velpatasvir. Clin Pharmacokinet. 2015. doi:10.1007/s40262-015-0334-7.
40. Mogalian E, Mathias A, Brainard D, McNally J, Moorehead L, Hernandez M, et al. The pharmacokinetics of GS-5816, a pan-genotype HCV NS5A inhibitor, in HCV-uninfected subject with moderate and severe hepatic impairment [abstract no. P742]. J Hepatol. 2014;60(Suppl. 1):S317. doi:10.1016/S0168-8278(14)60903-X.
41. Mogalian E, Mathias A, Brainard D, Shen G, McNally J, Sajwani K, et al. The pharmacokinetics of GS-5816, a pangenotypic HCV-specific NS5A inhibitor, in HCV-uninfected subjects with severe renal impairment [abstract no. P0712]. J Hepatol. 2015;62(Suppl. 2):S590–1. doi:10.1016/S0168-8278(15)30915-6.
42. Gilead Sciences. Safety, tolerability, pharmacokinetics, and antiviral activity of GS-9857 in subjects with chronic hepatitis C virus infection. US National Institues of Health, ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02185794. Accessed 14 Mar 2016.
43. Yeh WW, Fraser IP, Reitmann C, Caro L, Mitselos A, Denef JF, et al. Pharmacokinetic interaction Of HCV protease inhibitor MK-5172 and ritonavir in healthy subjects [abstract no. 52]. HEPDART, 8–12 Dec 2013, Hawaii.
44. Gentile I, Buonomo AR, Borgia F, Zappulo E, Castaldo G, Borgia G. MK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infection. Expert Opin Inv Drug. 2014;23(5):719–28. doi:10.1517/13543784.2014.902049.
45. Petry A, Brainard DM, Anderson MS, Mitselos A, Laethem T, Heriman I, et al. Safety, tolerability, and pharmacokinetics after single and multiple doses of MK-5172, a novel HCV NS3/4a protease inhibitor with potent activity against known resistance mutants, in healthy subjects [poster]. 61st annual meeting of the American association for the study of liver diseases, 29 Oct–2 Nov 2010, Boston, MA.
46. Caro L, Anderson MS, Du L, Palcza J, Han L, van Dyck K, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic relationship for MK-5172, a novel hepatitis C virus (HCV) NS3/4A protease inhibitor, in genotype 1 and genotype 3 HCV-infected patients [abstract no. 13716]. 62nd annual meeting of the American association for the study of liver diseases, 6–9 Nov 2011, San Francisco.
47. Marshall WL, Yeh WW, Bethel-Brown C, Stypinski D, Auger P, Brandquist C, et al. No evidence of pharmacokinetic drug-drug interaction in healthy subjects between coadministered grazoprevir (MK-5172)/elbasvir (MK-8742) and sofosbuvir [abstract no. P0910]. J Hepatol. 2015;62(Suppl. 2):S686. doi:10.1016/S0168-8278(15)31113-2.
48. Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H Jr, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386(10003):1537–45. doi:10.1016/S0140-6736(15)00349-9.
49. Jacobson IM, Poordad F, Firpi-Morell R, Everson GT, Verna EC, Bhanja S, et al. Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with child–pugh class B cirrhosis (C-salt part A) [abstract no. O008]. J Hepatol. 2015;62(Suppl. 2):S193–4. doi:10.1016/S0168-8278(15)30015-5.
50. FDA. Zepatier prescribing information. 2016. https://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf. Accessed 4 Mar 2016.
51. EMA. Viekirax product information. 2015. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003839/WC500183997.pdf. Accessed 29 Sept 2015.
52. Khatri A, Menon R, Marbury TC, Lawitz E, Podsadecki TJ, Mullally V, et al. Pharmacokinetics and safety of coadministered paritaprevir plus ritonavir (paritaprevir/r), ombitasvir, and dasabuvir in hepatic impairment. J Hepatol. 2015;63(4):805–12. doi:10.1016/j.jhep.2015.05.029.
53. EMA. Exviera product information. 2015. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003837/WC500182233.pdf. Accessed 29 Sept 2015.
54. Abbvie. Abbvie update U.S. Labels for viekira pak and technivie. 2015. http://abbvie.mediaroom.com/press_releases?item=122646. Accessed 23 Mar 2016.
55. FDA. FDA drug safety communication: FDA warns of serious liver injury risk with hepatitis C treatments viekira pak and technivie. 2015. http://www.fda.gov/Drugs/DrugSafety/ucm468634.htm. Accessed 27 Oct 2015.
56. FDA. Copegus prescribing information. 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021511s023lbl.pdf. Accessed 30 Sept 2015.
57. EMA. Rebetol product information. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000246/WC500048210.pdf. Accessed 29 Sept 2015.
58. Glue P, Schenker S, Gupta S, Clement RP, Zambas D, Salfi M. The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease. Br J Clin Pharmacol. 2000;49(5):417–21. doi:10.1046/j.1365-2125.2000.00186.x.
59. Brennan BJ, Wang K, Blotner S, Magnusson MO, Wilkins JJ, Martin P, et al. Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment. Antimicrob Agents Chemother. 2013;57(12):6097–105. doi:10.1128/aac.00608-13.
60. Gupta SK, Kantesaria B, Glue P. Exploring the influence of renal dysfunction on the pharmacokinetics of ribavirin after oral and intravenous dosing. Drug Discov Ther. 2014;8(2):89-95.
61. de Kanter CT, Koning L, Berden FA, Wasmuth JC, Grintjes-Huisman KJ, Becker B, et al. The ARRIBA concept: adequate resorption of ribavirin. Antivir Ther. 2015;20(5):515–20. doi:10.3851/imp2935.
62. van Vlerken LG, de Kanter CT, Boland GJ, van Loon AM, van Soest H, Koek GH, et al. Measuring ribavirin concentrations during the earliest stages of antiviral therapy for hepatitis C: potential relevance for treatment outcome. Ther Drug Monit. 2013;35(4):546–51. doi:10.1097/FTD.0b013e31828a9fbf.
63. Aqel B, Pungpapong S, Leise M, Werner KT, Chervenak AE, Watt KD, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. Hepatology. 2015;62(4):1004–12. doi:10.1002/hep.27937.
64. Saxena V, Nyberg L, Pauly M, Dasgupta A, Nyberg A, Piasecki B, et al. Safety and efficacy of simeprevir/sofosbuvir in hepatitis C infected patients with compensated and decompensated cirrhosis. Hepatology. 2015;62(3):715–25. doi:10.1002/hep.27922.
65. FDA. Olysio prescribing Information. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205123s001lbl.pdf. Accessed 13 Jan 2016.
66. Kalyan Ram B, Frank C, Adam P, Cynthia L, Maria H, Lennox J, et al. Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of hepatitis C in patients with end stage renal disease. J Hepatol. 2015;63(3):715-25. doi:10.1016/j.jhep.2015.06.004.
67. Czul F, Peyton A, O’Brien CB, Jeffers L, Martin P, Bhamidimarri KR. Safety, efficacy and tolerability in the treatment of patients with chronic hepatitis C and severe renal impairment [poster. no 2256]. 66th annual meeting of the American association for the study of liver diseases, 7–13 Nov 2015, San Fransisco.
68. Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015;313(17):1736–44. doi:10.1001/jama.2015.3868.
69. Kao JH, Heo J, Yoffe B, Sievert W, Jacobson I, Bessone F, et al. Efficacy and safety of daclatasvir in combination with asunaprevir in cirrhotic and non-cirrhotic patients with HCV genotype 1b: results of the HALLMARK-DUAL study [abstract no. P1300]. J Hepatol. 2015;60(Suppl. 1):S527–8. doi:10.1016/S0168-8278(14)61467-7.
70. Suda G, Kudo M, Nagasaka A, Furuya K, Yamamoto Y, Kobayashi T, et al. Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. J Gastroenterol. 2016. doi:10.1007/s00535-016-1162-8.
71. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence. Hepatology. 2016. doi:10.1002/hep.28446.
72. Leroy V, Angus P, Bronowicki JP, Dore G, Hezode C, Pianko S, et al. All-oral treatment with daclatasvir (DV) plus sofosbuvir (SOF) plus ribavirin (RBV) for 12 or 16 weeks in HCV genotype (GT) 3-infected patients with advanced fibrosis of cirrhosis: the ally-3+ phase 3 study [abstract no. lb-3]. 66th annual meeting of the American association for the study of liver diseases, 13–17 Nov 2015, San Fransisco.
73. Ho SB, Byrne S, Moon S, Zhu Y, Seyedkazemi S, Rossaro L, et al. Twelve weeks of sofosbuvir plus ribavirin effective for treatment of genotype 2 HCV in difficult to treat U.S. veterans with cirrhosis - results of the valor-HCV study [abstract no. 1041]. 66th annual meeting of the American association for the study of liver diseases, 13–17 Nov 2015, San Fransisco.
74. Kayali Z, Ashouri B. Prospectieve stuy for the efficacy of sofosbuvir and simeprevir +/- ribavirin in hepatitis C genotype 1 and 4 compensated cirrhotic patients. Single center study and real life expierence [abstract no. 1100]. 66th annual meeting of the American association for the study of liver diseases, 13–17 Nov 2015, San Fransisco.
75. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149(9):649–59. doi:10.1053/j.gastro.2015.05.010.
76. Bourliere M, Bronowicki JP, de Ledinghen V, Hezode C, Zoulim F, Mathurin P, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015;15(4):397–404. doi:10.1016/s1473-3099(15)70050-2.
77. Curry MP, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373(27):2618–28. doi:10.1056/NEJMoa1512614.
78. Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1075-86.
79. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370(21):1973–82. doi:10.1056/NEJMoa1402869.
80. Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, Sulkowski MS, et al. Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: the RUBY-1 study [abstract no. L01]. J Hepatol. 2015;62(Suppl. 2):S257. doi:10.1016/S0168-8278(15)30147-1.
81. Hezode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology. 2014;147(1):132–42.e4. doi:10.1053/j.gastro.2014.03.051.
82. Buti M, Agarwal K, Horsmans Y, Sievert W, Janczewska E, Zeuzem S, et al. Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C. Gastroenterology. 2014;146(3):744–53.e3. doi:10.1053/j.gastro.2013.11.047.
83. Zollner G, Fickert P, Silbert D, Fuchsbichler A, Marschall H-U, Zatloukal K, et al. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol. 2003;38(6):717–27. doi:10.1016/S0168-8278(03)00096-5.
84. Aguirre Valadez J, Garcia Juarez I, Rincon Pedrero R, Torre A. Management of chronic hepatitis C virus infection in patients with end-stage renal disease: a review. Ter Clin Risk Manag. 2015;11:329–38. doi:10.2147/tcrm.s74282.
85. Dalrymple LS, Koepsell T, Sampson J, Louie T, Dominitz JA, Young B, et al. Hepatitis C virus infection and the prevalence of renal insufficiency. Clin J Am Soc Nephrol. 2007;2(4):715–21. doi:10.2215/cjn.00470107.
86. Johnson CA, Simmons WD. Dialysis of drugs. Nephrology Pharmacy Associates. http://www.just.edu.jo/DIC/Manuals/Dialysis%20of%20Drugs.pdf. Accessed 23 Mar
87. Morello J, Rodriguez-Novoa S, Jimenez-Nacher I, Soriano V. Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. J Antimicrob Chemother. 2008;62(6):1174–80. doi:10.1093/jac/dkn421.
88. Larrat S, Stanke-Labesque F, Plages A, Zarski JP, Bessard G, Souvignet C. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob Agents Chemother. 2003;47(1):124–9.
89. de Kanter CTMM. Introducing clinical pharmacology to hepatitis C therapy. Nijmegen: Radboud University Medical Center; 2015.
90. Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 2009;65(8):757–73. doi:10.1007/s00228-009-0678-8.
91. Aitken AE, Richardson TA, Morgan ET. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol. 2006;46123–49. doi:10.1146/annurev.pharmtox.46.120604.141059.
92. Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos. 2008;36(2):205–16. doi:10.1124/dmd.107.018747.
93. Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1075–86. doi:10.1016/s0140-6736(14)61795-5.
94. Lawitz E, Poordad F, Gutierrez JA, Evans B, Hwang P, Howe A, et al. C-SWIFT: grazoprevir (MK-5172) + elbasvir (MK-8472) + sofosbuvir in treatment-naïve patients with hepatitis C virus genotype 1 infection, with and without cirrhosis, for durations of 4, 6 or 8 weeks (interim results) [abstract]. 65th annual meeting of the America association for the study of liver diseases, 7–11 Nov 2014, Boston, MA.
95. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Hepatol. 2006;13(5):316–21. doi:10.1111/j.1365-2893.2005.00680.x.
96. Qaqish RB, Pilot-Matias T, Yu Y, Redman R, Mobashery N, Asselah T, et al. Efficacy and safety of ombitasvir/paritaprevir/ritonavir co-administrated with ribavirin in adults with genotype 4 chronic hepatitis C infedction and cirrhosis (AGATE-1) [abstract no. 714]. 66th annual meeting of the American association for the study of liver diseases, 16–17 Nov 2015, San Fransisco.